补肺化瘀汤联合化疗治疗非小细胞肺癌的临床观察

发布时间：2019-03-01 18:55

【摘要】：目的:观察补肺化瘀汤联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效、安全性及其对血管内皮生长因子(VEGF)及免疫功能的影响。方法:选取2013年10月-2015年6月在我院接受治疗的NSCLC患者120例作为研究对象,按随机数字表法分为观察组和对照组,各60例。对照组患者给予GP(吉西他滨+顺铂)方案化疗,观察组患者在对照组基础上加用补肺化瘀汤,每日1剂,水煎取汁400 m L,分早晚2次温服。比较两组患者临床疗效及治疗前后血清VEGF-A、VEGF-B、VEGF-C和免疫指标(CD3~+、CD4~+、CD8~+、CD4~+/CD8~+)水平,并记录毒副反应发生情况。结果:观察组患者的临床有效率、疾病控制率分别为58.33%、85.00%,显著高于对照组的40.00%、68.33%,差异均有统计学意义(P0.05)。治疗前,两组患者VEGF及免疫指标水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者血清VEGF水平均显著降低,且观察组显著低于对照组,差异均有统计学意义(P0.05);两组患者CD4~+、CD4~+/CD8~+水平均显著降低,CD8~+显著升高,且观察组患者CD4~+、CD4~+/CD~8+均显著高于对照组,CD8+显著低于对照组,差异均有统计学意义(P0.05);对照组患者CD3~+显著降低,且显著低于观察组,差异均有统计学意义(P0.05)。观察组患者白细胞下降、血小板减少、血红蛋白下降、转氨酶升高、胆红素升高、消化道反应的发生率均显著低于对照组,差异有统计学意义(P0.05)。结论:补肺化瘀汤联合化疗治疗NSCLC疗效显著,能有效抑制患者VEGF水平,改善免疫功能,减轻毒副反应。
[Abstract]:Aim: to observe the clinical efficacy and safety of Bufei Huayu decoction combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC) and its effect on vascular endothelial growth factor (VEGF) (VEGF) and immune function. Methods: 120 NSCLC patients who were treated in our hospital from October 2013 to June 2015 were randomly divided into observation group (n = 60) and control group (n = 60). The patients in the control group were treated with GP (gemcitabine cisplatin) regimen. The patients in the observation group were treated with Bufei Huayu decoction on the basis of the control group, one dose per day, the juice was extracted from the decoction water for 400ml, and the patients in the observation group were given warm medicine twice in the morning and evening. The clinical efficacy, serum VEGF-A,VEGF-B,VEGF-C and immune indexes (CD3~, CD4~, CD8~, CD4~ / CD8~) before and after treatment were compared between the two groups, and the side effects were recorded. Results: the clinical effective rate and disease control rate in the observation group were 58.33% and 85.00% respectively, which were significantly higher than those in the control group (40.00%, 68.33%) (P0.05). Before treatment, there was no significant difference in the levels of VEGF and immune index between the two groups (P0.05). After treatment, the serum VEGF levels of the two groups were significantly decreased, and the observation group was significantly lower than that of the control group, the difference was statistically significant (P0.05). The levels of CD4~, CD4~ / CD8~ and CD8~ in the two groups were significantly decreased, and the CD4~, CD4~ / CD~8 in the observation group were significantly higher than those in the control group, while the CD8 in the observation group was significantly lower than that in the control group (P0.05). The CD3~ of the control group was significantly lower than that of the observation group (P0.05). The rate of leukopenia, thrombocytopenia, hemoglobin, transaminase, bilirubin and digestive tract reaction in the observation group were significantly lower than those in the control group (P0.05). Conclusion: Bufei Huayu decoction combined with chemotherapy is effective in the treatment of NSCLC, which can effectively inhibit the level of VEGF, improve the immune function and reduce the toxic and side effects.
【作者单位】：广西中医药大学附属瑞康医院呼吸内科;广西中医药大学附属瑞康医院神经内科;广西中医药大学附属瑞康医院放疗科;
【基金】：广西中医药民族医药传承创新专项课题(No.GZLC14-23) 广西医疗卫生适宜技术开发与推广应用项目(No.S2017056)
【分类号】：R734.2

【相似文献】